Company Overview

Organon & Co. is a global healthcare company focused on improving women’s health, while also maintaining a diversified portfolio of established pharmaceuticals and biosimilars. The company operates within the pharmaceuticals and healthcare industries, with a strategic emphasis on areas that have historically received less research and commercial focus. Organon generates revenue primarily through prescription medicines, leveraging both legacy brands and newer growth products.

The company was formed in 2021 as a spin-off from Merck & Co., Inc., inheriting a portfolio of established medicines and global commercial infrastructure. Since becoming an independent publicly traded company, Organon has positioned itself as a scaled operator in women’s health with durable cash flows from mature brands, using this foundation to invest in innovation, partnerships, and acquisitions.

Business Operations

Organon operates through three primary business segments: Women’s Health, Established Brands, and Biosimilars. The Women’s Health segment includes contraception, fertility, and gynecology products and represents the company’s strategic growth priority. The Established Brands segment consists of off-patent branded medicines across cardiovascular, respiratory, dermatology, and pain management areas, which provide stable revenue and cash flow. The Biosimilars segment focuses on biologic alternatives for immunology and oncology indications.

The company markets products across both domestic and international markets, with a strong commercial presence outside the United States. Organon controls manufacturing, regulatory, and distribution capabilities inherited from its former parent, and it collaborates with partners for development and commercialization of select assets. Key subsidiaries include Organon LLC and various regional operating entities supporting sales, manufacturing, and regulatory activities.

Strategic Position & Investments

Organon’s strategy centers on expanding its Women’s Health portfolio through targeted acquisitions, licensing agreements, and internal lifecycle management, while using cash flows from Established Brands to fund growth and reduce debt. The company has completed notable acquisitions such as Forendo Pharma Oy, strengthening its pipeline in women’s health, and Daré Bioscience, Inc. assets, enhancing its contraception portfolio.

In addition to acquisitions, Organon invests in early- to mid-stage partnerships focused on fertility, endometriosis, and reproductive health. The company also continues to selectively expand its Biosimilars portfolio, primarily through commercialization partnerships, positioning itself to benefit from long-term biologics patent expirations while managing development risk.

Geographic Footprint

Organon is headquartered in North America with its corporate headquarters in New Jersey, United States, and operates in approximately 140 markets worldwide. A significant portion of its revenue is generated outside the United States, particularly in Europe, Asia-Pacific, Latin America, and Africa, reflecting the global reach of its established brands portfolio.

The company maintains manufacturing and commercial operations across multiple continents, enabling localized market access and regulatory compliance. Its broad international footprint provides diversification across healthcare systems and economic cycles, and supports its strategy of serving women’s health needs in both developed and emerging markets.

Leadership & Governance

Organon is led by an experienced executive team with backgrounds in global pharmaceuticals, commercialization, and corporate finance. Leadership emphasizes disciplined capital allocation, operational efficiency, and long-term value creation through focused investment in women’s health.

• Kevin Ali – Chief Executive Officer
• Matthew Walsh – Chief Financial Officer
• Elizabeth Monteleone – Chief Legal Officer
• Christine Alva – Chief Communications Officer
• Richard Raines – Head of Women’s Health Commercial Operations